Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Test How Well Multiple Doses of BI 765423 Are Tolerated by Healthy Men

Phase 1

Active, not recruiting

Conditions: Healthy

Interventions: Drug: BI 765423
Drug: Placebo matching BI 765423

First Posted Date: 2024-01-30

Last Posted Date: 2024-11-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT06232252

Locations: 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium

A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight

Phase 3

Active, not recruiting

Conditions: Obesity
Overweight

Interventions: Drug: survodutide
Drug: Placebo matching BI 456906

First Posted Date: 2024-01-22

Last Posted Date: 2024-12-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 307

Registration Number: NCT06214741

Locations: 🇨🇳
Beijing Chao-Yang Hospital, Beijing, China
🇨🇳
Peking University People's Hospital, Beijing, China
🇨🇳
Beijing Pinggu Hospital, Beijing, China

and more 27 locations

A Study Based on Medical Records in Spain That Looks at Diarrhoea Control in People With Pulmonary Fibrosis Who Are Taking Nintedanib

Recruiting

Conditions: Idiopathic Pulmonary Fibrosis
Diarrhoea

First Posted Date: 2024-01-11

Last Posted Date: 2024-11-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 100

Registration Number: NCT06200714

Locations: 🇪🇸
Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
🇪🇸
Hospital Universitario de Cruces, Bizkaia, Spain
🇪🇸
Hospital Galdakao, Bizkaia, Spain

and more 16 locations

A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity

Phase 1

Recruiting

Conditions: Overweight
Obesity

Interventions: Drug: BI 456906
Drug: Placebo to BI 456906
Drug: Moxifloxacin
Drug: Placebo to moxifloxacin

First Posted Date: 2024-01-11

Last Posted Date: 2024-11-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 80

Registration Number: NCT06200467

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

A Study in Healthy People to Compare Two Different Tablets of BI 685509 and to Test How Food and Esomeprazole Influence the Amount of BI 685509 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Avenciguat (BI 685509) (intended commercial formulation (iCF))
Drug: Avenciguat (BI 685509) (trial formulation 2 (TF2))
Drug: esomeprazole

First Posted Date: 2024-01-05

Last Posted Date: 2024-03-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT06193811

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease

Phase 3

Active, not recruiting

Conditions: Obesity

Interventions: Drug: Survodutide
Drug: Placebo matching survodutide

First Posted Date: 2023-12-19

Last Posted Date: 2024-12-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 274

Registration Number: NCT06176365

Locations: 🇯🇵
Shimamura Kinen Hospital, Tokyo, Nerima-ku, Japan
🇯🇵
Chiba University Hospital, Chiba, Chiba, Japan
🇯🇵
Hosokawa Surgery Clinic, Aichi, Nagoya, Japan

and more 25 locations

A Study in Healthy Men to Test How BI 1291583 is Taken up by the Body

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1291583
Drug: [14C]-BI 1291583

First Posted Date: 2023-12-12

Last Posted Date: 2024-02-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14

Registration Number: NCT06166992

Locations: 🇳🇱
ICON, Groningen, Netherlands

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Phase 3

Recruiting

Conditions: Lung Cancer, Non-squamous, Non-small Cell

Interventions: Drug: zongertinib
Drug: pembrolizumab
Drug: cisplatin
Drug: carboplatin
Drug: pemetrexed

First Posted Date: 2023-11-30

Last Posted Date: 2024-12-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 270

Registration Number: NCT06151574

Locations: 🇵🇹
Hospital CUF Porto, Porto, Portugal
🇺🇸
Scripps Cancer Center Torrey Pines, La Jolla, California, United States
🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States

and more 89 locations

A Study in Healthy Men to Test How Well Different Doses of BI 1584862 Are Tolerated

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1584862
Drug: Placebo

First Posted Date: 2023-11-28

Last Posted Date: 2024-11-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT06148948

Locations: 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan

IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack

Phase 2

Recruiting

Conditions: Myocardial Infarction

Interventions: Drug: BI 765845
Drug: Placebo matching BI 765845

First Posted Date: 2023-11-18

Last Posted Date: 2024-11-26

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 350

Registration Number: NCT06139328

Locations: 🇺🇸
Valley Clinical Trials, Inc., Covina, California, United States
🇺🇸
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸
University of Florida Health Jacksonville, Jacksonville, Florida, United States

and more 81 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy